MarginsXMarginsX
Home › Markets › Health Care › IGC

IGC Pharma Inc. (IGC)

IGC trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.1750
-0.57% on the day
Market cap
$20.4M
Nano cap
Revenue · 2024
$1.3M
-5.5% on 2023
Net income · 2024
-$7.1M
-560.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 10-KT (us-gaap:Revenues), fiscal year ended 2025-03-31, https://www.sec.gov/Archives/edgar/data/1326205/000118518526000941/0001185185-26-000941-index.htm. Net income: SEC 10-KT (us-gaap:NetIncomeLoss), fiscal year ended 2025-03-31.

Profile

FieldValue
TickerIGC on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001326205
SEC industry codePharmaceutical Preparations
Incorporated inMD

Financials · 2024

LineValue
Revenue$1.3M
Net income-$7.1M
Operating income-$7.4M
Net margin-560.3%
Operating margin-585.8%
Revenue growth-5.5%
Cash$405K
Total assets$8.7M
P/E (computed)Net income was not positive
P/S (computed)16.1×

Warning signs

Cash runway
0.9 months
$377K cash at September 30, 2026
Share count, 1 year
+25.6%
2025-10-30 to 2026-11-03 · +83.1% over 3 years
Going-concern doubt
No
10-Q filed November 6, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Going Concern The Company assesses and determines its ability to continue as a going concern in accordance with the provisions of ASC Subtopic 205-40, Presentation of Financial Statements Going Concern , which requires the Company to evaluate whether there are conditions or events that raise substantial doubt about its ability to continue as a going concern."
10-Q 2026-11-06
Cash and burn$377K cash; operating cash flow -$1.3M a quarter.Report 2026-09-30
Shares outstanding116,687,169 (2026-11-03); 92,868,241 a year earlier; 63,734,439 three years earlier.Cover page 2026-11-03
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-01-06
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorMANOHAR CHOWDHRY & ASSOCIATES, Chennai, IndiaPCAOB Form AP 2026-03-23
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2027
2026-09-30
$328K-$2.0M-$1.4M$377K$1.6M$1.3M10-Q 2026-11-06
Q1 2027
2026-06-30
$265K-$2.9M-$1.4M$331K$2.0M$1.1M10-Q 2026-08-14
Q4 2026
2026-03-31
$317K-$2.4M-$1.2M$207K$1.6M$1.2M10-Q 2026-05-15
Q3 2026
2025-12-31
$350K-$726K-$1.2M$900K$134K$1.2M10-KT 2026-03-18
Q2 2026
2025-09-30
$191K-$1.8M-$2.1M$1.1M$136K$1.1M10-Q 2026-11-06
Q1 2026
2025-06-30
$328K-$1.6M-$1.4M$454K$136K$1.3M10-Q 2026-08-14
Q4 2025
2025-03-31
$330K-$1.2M-$730K$405K$137K$1.3M10-Q 2026-05-15
Q3 2025
2024-12-31
$257K-$1.8M-$1.3M$470K$137K$1.2M10-Q 2025-02-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM 424B5
424B52026-01-06
Latest annual report
FORM 10-KT
10-KT2026-03-18
Latest quarterly / interim
FORM 10-Q
10-Q2026-11-06
Latest current report
FORM 8-K
8-K2026-07-14
Latest proxy
FORM DEF 14A
DEFA14A2026-10-22

Source: SEC EDGAR submissions feed, 818 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-10.0%
1 month-33.3%
3 months-37.9%
Year to date-35.7%
1 year-50.0%
From 52-week high-50.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
SHPHShuttle Pharmaceuticals Holdings Inc.$4.24-6.40%$20.2M
CPHIChina Pharma Holdings Inc.$0.4800-7.35%$20.7M
CELUCelularity Inc.$0.6191-1.75%$20.1M
TXMDTherapeuticsMD Inc.$1.81-3.21%$20.9M
AYTUAytu BioPharma Inc.$1.82+1.68%$19.8M
ATOSAtossa Therapeutics Inc.$1.93-1.53%$19.3M
COCPCocrystal Pharma Inc.$0.9777-0.24%$18.8M
LPCNLipocine Inc.$1.66-2.92%$18.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier